Comparison of Two Ventilation Methods During Endoscopy of the Pharynx, Larynx and Oesophag
Around 15,000 ENT cancers are diagnosed each year in France. The majority of these cancers will at one time or another require an Endoscopy of the Pharynx, Larynx and Esophagus (Endo-PLE or suspension laryngoscopy). Endoscopies of the Otorhinolaryngeal (ENT) sphere are common procedures. They consist of inserting a rig
| Condition(s) | Oxygen Inhalation Therapy Endoscopy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Around 15,000 ENT cancers are diagnosed each year in France. The majority of these cancers will at one time or another require an Endoscopy of the Pharynx, Larynx and Esophagus (Endo-PLE or suspension laryngoscopy). Endoscopies of the Otorhinolaryngeal (ENT) sphere are common procedures. They consist of inserting a rigid laryngoscope through the mouth, allowing full exposure of the laryngeal sphere. They are performed in most cases as part of a swelling assessment, following CT scans, or following the discovery of a mass upon palpation of the patient. Unfortunately, these are aggressive cancers that subsequently require major surgery and additional treatment by radio or chemotherapy. This examination can also be performed on patients suffering from swallowing disorders, following the appea |
| Who can participate | Inclusion Criteria: * Patient aged 18 or over. * Not requiring oxygen. * About to undergo exclusive Endoscopy of the pharynx, larynx and oesophagus surgery. * Score de l'American Society of Anesthesiology between 1 and 4 * Informed consent signed Exclusion Criteria: * Endoscopy of the pharynx, larynx and oesophagus surgery combined with another procedure * Severe or morbid obesity (BMI ≥ 35 kg/m²) * Patients with stage IV chronic obstructive pulmonary disease * Allergy to one of the drugs used in anaesthesia, remifentanil and/or propofol and/or lidocaine. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Poitiers University Hospital |
| Locations | Poitiers, France; Poitiers, France |
| Start date | 2025-07-11 |
| NCT ID | NCT07004699 |
| Official listing | https://clinicaltrials.gov/study/NCT07004699 |